Table 4.
MMP3 and/or CCN2/CTGF expression correlated with the prognosis of cancer patients.
| Tumor Region | MMP3 | CCN2/CTGF | Correlation |
|---|---|---|---|
| Lung | p = 0.035 * | p = 0.05 * | MMP3-high, CTGF-high; poor prognosis |
| Head & Neck | p = 0.051 | p = 0.018 * | MMP3-high, CTGF-high; poor prognosis |
| Melanoma | p = 0.071 | p = 0.17 | MMP3-high, CTGF-high; poor prognosis |
| Glioma | p = 0.35 | p = 0.13 | MMP3-high, CTGF-high; poor prognosis |
| Pancreatic | p = 0.00041 **** | p = 0.24 | MMP3-high; poor prognosis |
| Cervical | p = 0.00097 **** | p = 0.14 | MMP3-high; poor prognosis |
| Prostate | p = 0.033 * | p = 0.21 | MMP3-high; poor prognosis |
| Stomach | p = 0.32 | p = 0.0005 **** | CTGF-high; poor prognosis |
| Urothelial | p = 0.23 | p = 0.0038 *** | CTGF-high; poor prognosis |
| Colorectal | p = 0.0016 *** | p = 0.044 * | CTGF-high; poor prognosis |
| Breast | p = 0.23 | p = 0.29 | CTGF-high; poor prognosis |
| Endometrial | p = 0.0051 ** | p = 0.057 | MMP3-high, CTGF-high; better prognosis |